Esoglaz-D Capsule PR is a combination pharmaceutical formulation containing Domperidone 30 mg and Esomeprazole 40 mg, designed to manage gastrointestinal disorders associated with acid reflux and motility disturbances. Domperidone, a peripheral dopamine D2 receptor antagonist, enhances gastrointestinal motility by accelerating gastric emptying and improving esophageal sphincter tone, thereby reducing symptoms such as nausea, vomiting, and bloating. Esomeprazole, a proton pump inhibitor (PPI), selectively inhibits the H+/K+ ATPase enzyme system at the secretory surface of gastric parietal cells, effectively suppressing gastric acid secretion. This dual-action capsule is indicated for the treatment of gastroesophageal reflux disease (GERD), erosive esophagitis, and conditions requiring acid suppression combined with prokinetic activity. The prolonged-release formulation ensures sustained therapeutic plasma levels, improving patient compliance and symptom control. Esoglaz-D Capsule PR should be administered as prescribed, typically once daily before meals, and is contraindicated in patients with known hypersensitivity to either component or in those with prolactin-releasing pituitary tumors. Caution is advised in patients with hepatic impairment or cardiac arrhythmias. Potential adverse effects include headache, dry mouth, abdominal discomfort, and, rarely, extrapyramidal symptoms. Regular monitoring and consultation with a healthcare professional are recommended during therapy.